Journal of the Neurological Sciences最新文献_第6页

Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease 同时服用埃索美拉唑对帕金森病患者左旋多巴药代动力学和临床症状的影响

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-28 DOI: 10.1016/j.jns.2024.123202

{"title":"Effect of concomitant use of esomeprazole on levodopa pharmacokinetics and clinical symptoms in patients with Parkinson's disease","authors":"","doi":"10.1016/j.jns.2024.123202","DOIUrl":"10.1016/j.jns.2024.123202","url":null,"abstract":"<div><h3>Background</h3><p>Proton pump inhibitors (PPIs), which inhibit gastric acid secretion, are frequently prescribed to patients with Parkinson's disease (PD). Levodopa, the gold-standard treatment for PD, demonstrates enhanced solubility in acidic environments. Although PPIs increase gastric pH and may affect levodopa absorption, the effect of concomitant PPI use on levodopa pharmacokinetics in patients with PD remains unknown. This study aimed to investigate the effect of the concomitant use of esomeprazole, a PPI, on the pharmacokinetics of levodopa and carbidopa and clinical symptoms in patients with PD.</p></div><div><h3>Methods</h3><p>We prospectively enrolled 40 patients with PD and compared the pharmacokinetics of levodopa and carbidopa and clinical symptoms before and two weeks after the concomitant use of esomeprazole.</p></div><div><h3>Results</h3><p>The plasma concentrations of levodopa 30 min after concomitant oral administration of levodopa and esomeprazole were significantly lower (4.92 ± 4.10 μmol/L) than those without concomitant esomeprazole use (6.26 ± 3.75 μmol/L; <em>p</em> = 0.027). The plasma concentrations of carbidopa showed no significant differences with respect to concomitant esomeprazole use. Significant elevation was recorded in all subscores of the Movement Disorder Society-sponsored revision of the Unified Parkinson's disease Rating Scale scores after concomitant use of esomeprazole. No significant differences were observed between <em>Helicobacter pylori</em>-negative and <em>Helicobacter pylori</em>-positive patients. Non-elderly patients (age ≤ 70 years) tended to be more susceptible to the effect of esomeprazole on levodopa pharmacokinetics and clinical symptoms.</p></div><div><h3>Conclusions</h3><p>The unnecessary use of PPIs should be avoided in patients with PD, especially in non-elderly patients, to improve absorption of levodopa.</p></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor: Increasing incidence of Parkinson's disease in patients with epilepsy: A Nationwide Cohort Study 致编辑的信：癫痫患者帕金森病的发病率越来越高：全国队列研究

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-27 DOI: 10.1016/j.jns.2024.123206

引用次数: 0

Integrative analysis of molecular pathways and morphological anomalies associated with congenital Zika syndrome 与先天性寨卡综合征相关的分子途径和形态异常的综合分析。

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-22 DOI: 10.1016/j.jns.2024.123190

{"title":"Integrative analysis of molecular pathways and morphological anomalies associated with congenital Zika syndrome","authors":"","doi":"10.1016/j.jns.2024.123190","DOIUrl":"10.1016/j.jns.2024.123190","url":null,"abstract":"<div><p>Congenital Zika syndrome (CZS) comprises a set of clinical manifestations that can be presented by neonates born to mothers infected by the Zika virus (ZIKV). CZS-associated phenotypes include neurological, skeletal, and systemic alterations and long-term developmental sequelae. One of the most frequently reported clinical conditions is microcephaly characterized by a reduction in head circumference and cognitive complications. Nevertheless, the associations among the diverse signaling pathways underlying CZS phenotypes remain to be elucidated. To shed light on CZS, we have extensively reviewed the morphological anomalies resulting from ZIKV infection, as well as genes and proteins of interest obtained from the published literature. With this list of genes or proteins, we performed computational analyses to explore the cellular processes, molecular mechanisms, and molecular pathways related to ZIKV infection. Therefore, in this review, we comprehensively describe the morphological abnormalities caused by congenital ZIKV infection and, through the analysis noted above, propose common molecular pathways altered by ZIKV that could explain both central nervous system and craniofacial skeletal alterations.</p></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comment on: Evaluation of the T25FW in minimally disabled people with multiple sclerosis 评论对 T25FW 在轻度残疾的多发性硬化症患者中的应用进行评估。

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-22 DOI: 10.1016/j.jns.2024.123189

引用次数: 0

Post-acute sequelae of SARS-CoV-2 mimic: An important neurological condition 模仿 SARS-CoV-2 的急性后遗症：一种重要的神经系统疾病

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-22 DOI: 10.1016/j.jns.2024.123199

{"title":"Post-acute sequelae of SARS-CoV-2 mimic: An important neurological condition","authors":"","doi":"10.1016/j.jns.2024.123199","DOIUrl":"10.1016/j.jns.2024.123199","url":null,"abstract":"<div><h3>Background and objectives</h3><p>In 2024, the sequalae of the acute phase of coronavirus disease-19 (COVID-19) infection, which include neurological symptoms and are commonly referred to as long COVID or post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC), continue to be a substantial health concern; however, similar symptoms are observed in individuals with no previous COVID-19 infection.</p></div><div><h3>Methods</h3><p>This was a single-center, retrospective, descriptive case series study. Data were obtained from patients who visited our outpatient clinic specializing in PASC between June 1, 2021, and May 31, 2023. We compared antibody test results between patients with confirmed acute phase infection and those without. We compared differences in demographic and clinical characteristics between patients with positive results during the acute phase of COVID-19 infection and positive anti-SARS-CoV-2 antibody tests (true-PASC), and those with neither (PASC-mimic).</p></div><div><h3>Results</h3><p>Of 437 patients diagnosed with PASC according to World Health Organization criteria, 222 underwent COVID-19 antibody tests. Of these, 193 patients (86.9%) had a history of confirmed acute phase infection, whereas 29 (13.1%) did not. Of the former, 186 patients (96.4%) were seropositive for anti-nucleotide SARS-CoV-2 antibodies (true-PASC), whereas 19 of the latter tested seronegative for anti-nucleotide SARS-CoV-2 antibodies (PASC-mimic). There were no significant differences in symptom characteristics between true-PASC and PASC-mimic participants.</p></div><div><h3>Conclusions</h3><p>It was difficult to identify any clinical features to aid in diagnosing PASC without confirmation of acute COVID-19 infection. The findings indicate the existence of a “PASC-mimic” condition that should be acknowledged and excluded in future PASC-related research studies.</p></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0022510X24003344/pdfft?md5=3b11d8e68e0b4667439db827c7b5e392&pid=1-s2.0-S0022510X24003344-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dopaminergic progenitors generated by small molecule approach survived, integrated, and promoted functional recovery in (6-OHDA) mouse model of Parkinson's disease 小分子方法产生的多巴胺能祖细胞在（6-OHDA）帕金森病小鼠模型中存活、整合并促进功能恢复

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-20 DOI: 10.1016/j.jns.2024.123188

{"title":"Dopaminergic progenitors generated by small molecule approach survived, integrated, and promoted functional recovery in (6-OHDA) mouse model of Parkinson's disease","authors":"","doi":"10.1016/j.jns.2024.123188","DOIUrl":"10.1016/j.jns.2024.123188","url":null,"abstract":"<div><p>Parkinson's disease (PD) is a neurodegenerative disorder resulting from the loss of dopamine-producing neurons in the brain, causing motor symptoms like tremors and stiffness. Although current treatments like medication and deep brain stimulation can alleviate symptoms, they don't address the root cause of neuron loss. Therefore, cell replacement therapy emerges as a promising treatment strategy. However, the generation of engraftable dopaminergic (DA) cells in clinically relevant quantities is still a challenge. Recent advances in cell reprogramming technologies open up vast possibilities to produce patient-specific cells of a desired type in therapeutic quantities. The main cell reprogramming strategies involve the enforced expression of individual or sets of genes through viral transduction or transfection, or through small molecules, known as the chemical approach, which is a much easier and safer method. In our previous studies, using a small molecule approach (combinations of epigenetic modifiers and SMAD inhibitors such asDorsomorphin and SB431542), we have been able to generate DA progenitors from human mesenchymal stem cells (hMSCs). The aim of this study was to further improve the method for the generation of DA progenitors and to test their therapeutic effect in an animal model of Parkinson's. The results showed that the addition of an autophagy enhancer (AE) to our DA cell induction protocol further increased the yield of DA progenitor cells. The results also showed that DA progenitors transplanted into the mouse model of PD survived, integrated, and improved PD motor symptoms. These data suggest that chemically-produced DA cells can be very promising and safe cellular therapeutics for PD.</p></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adrenocorticotropic hormone therapy alters Q-albumin ratios in patients with infantile epileptic spasms syndrome of unknown etiology 肾上腺皮质激素疗法会改变病因不明的婴儿癫痫痉挛综合征患者的 Q-白蛋白比率

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-16 DOI: 10.1016/j.jns.2024.123187

{"title":"Adrenocorticotropic hormone therapy alters Q-albumin ratios in patients with infantile epileptic spasms syndrome of unknown etiology","authors":"","doi":"10.1016/j.jns.2024.123187","DOIUrl":"10.1016/j.jns.2024.123187","url":null,"abstract":"<div><h3>Purpose</h3><p>Infantile epileptic spasms syndrome (IESS) with epileptic spasms as the main seizure type, is treated with adrenocorticotropic hormone (ACTH). This study, for the first time, examines the effects of epileptic spasms and ACTH on blood-brain barrier (BBB) permeability in patients with IESS of unknown etiology.</p></div><div><h3>Methods</h3><p>We prospectively evaluated the changes in BBB permeability in patients with IESS of unknown etiology at the Saitama Children's Medical Center between February 2012 and February 2024. We compared the levels of serum-albumin, cerebrospinal fluid (CSF)-albumin, Q-albumin, and CSF-neuron-specific enolase (NSE) before and after ACTH therapy. We also assessed the correlation between the frequency of epileptic spasms and these markers.</p></div><div><h3>Results</h3><p>Overall, 16 patients with IESS (8 males) were included in the study. The median age at IESS onset was 5 (range, 2–9) months. The median duration between the epileptic spasms onset and the serum and CSF sample examination before ACTH therapy was 26 (range, 1–154) days. After ACTH therapy, CSF-albumin and Q-albumin levels significantly decreased (CSF-albumin: 13.5 (9.0–32.0) mg/dL vs 11.0 (7.0–19.0) mg/dL, <em>p</em> = 0.001. Q-albumin: 3.7× 10<sup>−3</sup> (2.2 × 10<sup>−3</sup>-7.3 × 10<sup>−3</sup>) vs 2.8× 10<sup>−3</sup> (1.9 × 10<sup>−3</sup>-4.5 × 10<sup>−3</sup>), <em>p</em> = 0.003). No correlation was observed between the epileptic spasms frequency and levels of serum-albumin, CSF-albumin, Q-albumin, and CSF-NSE (Spearman's coefficient: <em>r</em> = 0.291, <em>r</em> = 0.141, <em>r</em> = 0.094, and <em>r</em> = −0.471, respectively).</p></div><div><h3>Conclusion</h3><p>ACTH therapy is one of the factors that play a role in restoring BBB permeability in patients with IESS of unknown etiology. Our findings may be useful in elucidating the mechanism of ACTH action and IESS pathophysiology.</p></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

World Brain Day 2024: Promoting brain health and prevention 2024 年世界脑日：促进大脑健康和预防

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-15 DOI: 10.1016/j.jns.2024.123095

引用次数: 0

Response to Prof. Robert Colebunders' Letter submitted to JNS regarding: Spencer PS, Valdes Angues R, Palmer VS. Nodding syndrome: A role for environmental biotoxins that dysregulate MECP2 expression? J Neurol Sci. 2024 Jul 15;462:123077. doi: 10.1016/j.jns.2024.123077 对罗伯特-科勒本德斯教授提交给 JNS 的有关信件的回应：Spencer PS, Valdes Angues R, Palmer VS.点头综合征：环境生物毒素对 MECP2 表达的调节作用？J Neurol Sci. 2024 Jul 15;462:123077. doi: 10.1016/j....

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-15 DOI: 10.1016/j.jns.2024.123153

引用次数: 0

Thoracic paraspinal muscles denervation assessment in amyotrophic lateral sclerosis: Clinical-neurophysiological correlations and prognostic value 肌萎缩性脊髓侧索硬化症胸椎旁肌肉神经支配评估：临床神经生理学相关性和预后价值。

IF 3.6 3区医学

Journal of the Neurological Sciences Pub Date : 2024-08-15 DOI: 10.1016/j.jns.2024.123133

引用次数: 0